| Research Article |
Open Access |
|
| Assessment of Bioavailability of Rifampicin as a Component
of Anti-tubercular Fixed Dose Combination Drugs Marketed in
Pakistan |
| Shahzad Hussain6* , Farnaz Malik1, Wajahat Mehmood2, Abdul Hameed3, Humanyun Riaz5 , and Muhammad Rizwan4 |
| 1NIH, PAKISTAN |
| 2DCTMD, NIH, Islamabad, Pakistan |
| 3Menzies University, Australia |
| 4QAU, Islamabad, Pakistan |
| 5Punjab university, Lahore Pakistan |
| 6Telemedicines Department, Holy Familly hospital, Rawalpindi, Pakistan |
| *Corresponding author: |
Shahzad Hussain,
NIH, PAKISTAN,
E-mail: shshaikh2001@yahoo.com |
|
| |
| Received February 12, 2010; Accepted May 12, 2010; Published May 12, 2010 |
| |
| Citation: Hussain S, Malik F, Mehmood W, Hameed A, Riaz H, et al. (2010)
Assessment of Bioavailability of Rifampicin as a Component of Anti-tubercular
Fixed Dose Combination Drugs Marketed in Pakistan. J Bioequiv Availab 2: 067-
071. doi:10.4172/jbb.1000033 |
| |
| Copyright: © 2010 Hussain S, et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and
source are credited. |
| |
| Abstract |
| The World Health Organization (WHO) recommended DOTS program recommends treatment of TB with a
combination of three to five drugs. However, international bodies like the WHO and IUTLD (international union against
tuberculosis and ling disease) recommend the use of only those fixed dose combinations that have proven in vivo
bioavailability. The present study was conducted to test the in vivo bioavailability of some of the formulations currently
marketed in Pakistan on twenty six healthy volunteers as a three sequence, three period cross-over study. Rifampicin
was administered in three different formulations out of which one (Formulation A) acted as a standard against which
the other two formulations; Formulation B (Fixed dose combination without pyrazinamide) and formulation C (Fixed
dose combination with pyrazinamide) were tested. Thirteen blood samples including a pre-dose sample were drawn
over a period of 24 hours. Plasma samples were analyzed for rifampicin concentration by an HPLC method and critical
pharmacokinetic parameters were calculated. Although, based on the confi dence intervals for the ratios of geometric
means of pharmacokinetic parameters none of the test formulations B or C could be declared bioequivalent, nevertheless
effective formulations for the treatment of TB in Pakistan. |
| |
|
This Article |
DOWNLOAD |
|
Services |
|
Google Scholar |
|
Pub Med |
|
|
